Myricetin inhibits panel of kinases implicated in tumorigenesis

22Citations
Citations of this article
21Readers
Mendeley users who have this article in their library.

Abstract

Myricetin is a flavonoid with several biological properties, including antioxidant and anti-inflammatory features. Its protective effect in chronic diseases may occur through the inhibition of protein kinases that trigger inflammation and carcinogenesis pathways. Considering the influence of kinases on such pathological disorders, it is crucial to study compounds that inhibit these proteins. This study aims to evaluate the inhibitory potential of 14 flavonoids on TNF-α release in human whole blood as well as the inhibitory potential of myricetin towards kinases involved in tumorigenesis. Our results showed that, out of all flavonoids, myricetin had the highest inhibitory effect on TNF-α level. In addition, myricetin showed potential as a multi-anti-kinase compound, reducing the activity of 7 kinases by >70% and of 9 kinases by >90%. Together these data demonstrate the great inhibitory activity of myricetin on tumorigenic kinases and potential for the development of new therapeutics.

Author supplied keywords

Cite

CITATION STYLE

APA

Stoll, S., Bitencourt, S., Laufer, S., & Inês Goettert, M. (2019). Myricetin inhibits panel of kinases implicated in tumorigenesis. Basic and Clinical Pharmacology and Toxicology, 125(1), 3–7. https://doi.org/10.1111/bcpt.13201

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free